ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Biologic agents"

  • Abstract Number: 2391 • 2013 ACR/ARHP Annual Meeting

    Pathogenic Pro-Inflammatory Cytokine Production Induced By Synovial Fluid From RA Patients Is Related To Levels Of Endogenous TLR4 Ligands and Is Blocked By a Novel Therapeutic Anti-Human TLR4 Monoclonal Antibody, NI-0101

    Limin Shang1, Greg Elson1, Jeremy Sokolove2, Iain B. McInnes3, James Reilly4, Eric Hatterer1, Marie Kosco-Vilbois5, Walter Ferlin5, Emmanuel Monnet5 and Cristina de Min6, 1NovImmune S.A., Plan-Les-Ouates, Geneva, Switzerland, 2VA Palo Alto Healthcare System and Stanford University, Palo Alto, CA, 3Glasgow Biomedical Research Centre, University of Glasgow, Glasgow, United Kingdom, 4University of Glasgow, Glasgow, United Kingdom, 5NovImmune S.A., Geneva, Switzerland, 6Novimmmune S.A., Plan-Les-Ouates, Geneva, Switzerland

    Background/Purpose: Deregulation of Toll-Like Receptor 4 (TLR4) signaling is thought to play a role in the pathogenesis of certain autoimmune diseases. In rheumatoid arthritis (RA),…
  • Abstract Number: 1750 • 2013 ACR/ARHP Annual Meeting

    Short and Long-Term Biological Therapy In Refractory Uveitis Of Behcet’s Syndrome. Multicenter Study Of 124 Patients

    Francisco Ortiz-Sanjuan1, Vanesa Calvo-Río2, Ricardo Blanco3, Emma Beltrán4, Juan Sánchez-Bursón5, Marina Mesquida6, Alfredo M. Adan6, M Hernandez Grafella7, E Valls Pascual8, L Martínez-Costa9, Agustí Sellas-Fernàndez10, Miguel Cordero-Coma11, Manuel Diaz-llopis12, David Salom12, Jl García Serrano13, Norberto Ortego13, JM Herreras14, Alejandro Fonollosa15, A Aparicio16, O Maíz17, A Blanco18, I Torre19, Cruz Fernández-Espartero20, V Jovani21, D Peitado-Lopez22, Esperanza Pato23, J Cruz24, J. Carlos Fernandez-Cid25, E. Aurrecoechea26, M García27, M Caracuel28, Carlos Montilla29, A Atanes30, F Francisco31, S Insua32, S González-Suárez33, A Sánchez-Andrade34, F Gamero35, Luis Linares36, F Romero-Bueno37, AJ García González38, Raquel Almodovar39, E Minguez40, C Carrasco Cubero41, Alejandro Olive Marques42, J Vázquez43, O Ruiz Moreno44, F Jimenez-Zorzo44, J Manero44, Javier Loricera1 and Miguel Angel González-Gay1, 1Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander. Spain, Santander, Spain, 2Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, 3Hospital Marques de Valdecilla, Santander, Spain, 4Rheumatology, Hospital General Universitario de Valencia. Spain, Valencia, Spain, 5Hospital de Valme. Sevilla, Sevilla, Spain, 6Ophthalmology, Hospital Clínic of Barcelona, Barcelona, Spain, 7Ophthalmology, Hospital General Universitario, Valencia, Valencia, Spain, 8Rheumatology, Hospital Peset Valencia, Valencia, Spain, 9Ophthalmology, Hospital Peset Valencia, Valencia, Spain, 10Rheumatology, Hospital Val d´Hebron. Barcelona, Barcelona, Spain, 11Departament of Ophthalmology, Hospital de León, León, Spain, 12Department of Ophthalmology, Hospital Universitario La Fe de Valencia, Valencia, Spain, 13Hospital San Cecilio. Granada, Granada, Spain, 14Hospital Universitario, IOBA. Valladolid, Valladolid, Spain, 15Ophtalmology Service, Hospital de Cruces. Bilbao, Bilbao, Spain, 16Rheumatology., Hospital de Toledo., Toledo, Spain, 17Rheumatology, Hospital Donosti San Sebastian, San Sebastián, Spain, 18Ophthalmology., Hospital Donosti San Sebastian, San Sebastián, Spain, 19Rheumatology., Hospital Basurto. Bilbao, Bilbao, Spain, 20Servicio de Reumatología, Hospital Universitario de Móstoles, Madrid, Spain, 21Rheumatology., Hospital General de Alicante., Alicante, Spain, 22Rheumatology, Hospital Universitario La Paz Madrid, Madrid, Spain, 23Rheumatology, Hospital Clínico San Carlos. Madrid, Madrid, Spain, 24Rheumatology, Hospital de Pontevedra, Pontevedra, Spain, 25Departament of Ophthalmology, Hospital de Pontevedra, Pontevedra, Spain, 26Hospital Sierrallana. Torrelavega, Torrelavega, Spain, 27Rheumatology., Hospital La Princesa. Madrid, Madrid, Spain, 28Rheumatology., Hospital de Córdoba., Córdoba, Spain, 29Unit Rheumatology, Hospital Universitario de Salamanca, Salamanca, Spain, 30Rheumatology., HUCA La Coruña., A Coruña, Spain, 31Rheumatology., Hospital Doctor Negrín Canarias., Canarias, Spain, 32Rheumatology., Hospital Universitario Santiago de Compostela, Santiago de Compostela, Spain, 33Rheumatology., Hospital Cabueñes, Gijón, Gijón, Spain, 34Rheumatology., Hospital Lucus Augusti Lugo, Lugo, Spain, 35Rheumatology., Hospital San Pedro Alcantara Caceres, Caceres, Spain, 36Rheumatology, Hospital Universitario Virgen de la Arrixaca. Murcia, Murcia, Spain, 37Rheumatology., Fundación Jimenez Díaz. Madrid, Madrid, Spain, 38Rheumatology., Hospital 12 de Octubre. Madrid, Madrid, Spain, 39Rheumatology Unit, Hospital Universitario Fundación Alcorcón. Madrid, Alcorcon. Madrid, Spain, 40Ophthalmology, Hospital Clínico de Zaragoza, Zaragoza, Spain, 41Rheumatology., Hospital de Mérida, Mérida, Spain, 42Hospital Germans Trias i Pujol. Badalona, Barcelona, Spain, 43Rheumatology, Hospital de Ferrol. A Coruña, A Coruña, Spain, 44Hospital Universitario Miguel Servet. Zaragoza, Zaragoza, Spain

    Background/Purpose: To evaluate short and long-term response to biological therapy in uveitis associated to Behçet´s syndrome refractory to standard systemic treatment. Methods: Multicenter study of…
  • Abstract Number: 1339 • 2013 ACR/ARHP Annual Meeting

    Efficacy and Safety Of Biologics Agents For Patients With Rheumatoid Arthritis and Hepatitis B Carrier

    Masahiro Tada1, Tatsuya Koike2, Akihiro Tamori3, Tadashi Okano1, Yuko Sugioka1, Kenji Mamoto1, Kentaro Inui4 and Hiroaki Nakamura1, 1Orthopedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, 2Rheumatosurgery, Osaka City University Graduate School of Medicine, Osaka, Japan, 3Hepatiology, Osaka City University Graduate School of Medicine, Osaka, Japan, 4Orhtopedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan

    Background/Purpose: Biologics suppress hepatitis B virus (HBV) replication and play an important role in eradicating HBV by stimulating HBV-specific cytotoxic T-cell responses. We found that…
  • Abstract Number: 354 • 2013 ACR/ARHP Annual Meeting

    Disease Burden Among Patients With Psoriatic Arthritis Who Have Experienced First Line Tumor Necrosis Factor Inhibitor Regimen Failure In The European Union

    Siva Narayanan1, Yao Lu2, Richard Hutchings2 and Amanda Baskett2, 1Evidence Generation, Value and Access Center, Ipsos Healthcare, Columbia, MD, 2Ipsos Healthcare, London, United Kingdom

    Background/Purpose: Data on second line biologic patients who have experienced 1st line tumor necrosis factor inhibitor (TNF) failure and associated disease burden among patients (pts)…
  • Abstract Number: 2375 • 2013 ACR/ARHP Annual Meeting

    Tocilizumab Glucocorticoids Sparing Effect: The Spare-1 Study

    Alain Saraux1, Stephanie Rouanet2, Rene-Marc Flipo3, Jean-Cyril Poncet4, Patrice Fardellone5, Pascal Hilliquin6, Isabelle Idier7 and Alain G. Cantagrel8, 1Department of rheumatology and unit of immunology (EA 2216), CHU Brest et Université Bretagne Occidentale, Brest, France, 2Medical Department, Roche, Boulogne-Billancourt, France, 3Rheumatology, University Hospital Lille, Lille, France, 4Rheumatology, General Hospital Gap, Gap, France, 5Service de Rhumatologie, Hôpital Nord, C.H.U. d'Amiens, Amiens, France, 6Rheumatology, General Hospital Corbeil, Corbeil-Essonnes, France, 7Chugai Pharma, La Defense, France, 8Rheumatology, CHU Purpan - Hôpital Pierre-Paul Riquet, Toulouse, France

    Background/Purpose:  Although glucocorticoids (GCs) may be appropriate in rheumatoid arthritis (RA), there is general agreement that GCs sparing is desirable. The safety of GCs is…
  • Abstract Number: 1733 • 2013 ACR/ARHP Annual Meeting

    Early and Sustained Improvement In Pain and Physical Function As Measured By Visual Analog Scale and Short Form-36 Physical Component Summary Score In Rheumatoid Arthritis Patients Treated With Mavrilimumab, An Investigational Anti-GM-CSFR-Alpha Monoclonal Antibody, In a Phase 2a Study

    Gerd Burmester1, Tsutomu Takeuchi2, Olga Barbarash3, Duncan Porter4, Didier Saurigny5, David Close5, Alex Godwood5, Yoojung Yang6 and Ancilla W. Fernandes6, 1Rheumatology and Clinical Immunology, Campus Mitte, Charite University Hospital, Berlin, Germany, 2Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, 3SIH Kemerovo Regional Clinical Hospital, Kemerovo, Russia, 4Rheumatology, Gartnavel General Hospital, Glasgow, United Kingdom, 5MedImmune, Ltd, Cambridge, United Kingdom, 6MedImmune, LLC, Gaithersburg, MD

    Background/Purpose: Rheumatoid arthritis (RA) is associated with significant pain and loss of physical function. We evaluated self-reported pain and physical function in adults patients with…
  • Abstract Number: 1232 • 2013 ACR/ARHP Annual Meeting

    Osteoporosis In Rheumatoid Arthritis – Still a Threat In The Biologic Era?

    Glenn Haugeberg1, Torhild Garen2, Hege Sommerseth3, Anne Prøven3 and Knut Helgetveit3, 1Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, 2Department of Rheumatology, Oslo University Hospital Rikshospitalet, Oslo, Norway, 3Rheumatology, Martina Hansens Hospital, Bærum, Norway

    Background/Purpose: Osteoporosis is a well-known extra articular manifestation in rheumatoid arthritis (RA). In RA biologic disease modifying anti rheumatic drugs (DMARDs) has been shown to…
  • Abstract Number: 335 • 2013 ACR/ARHP Annual Meeting

    Comparing Adalimumab and Etanercept As First Line Agents In Patients With Psoriatic Arthritis. Data From The Rhumadata® Clinical Database and Registry

    Sabrina Hoa1, Denis Choquette2, Louis Bessette3, Diane Sauvageau4, Boulos Haraoui4, Jean Pierre Pelletier2, Jean-Pierre Raynauld4, Edith Villeneuve4 and Louis Coupal2, 1Rheumatology, Centre hospitalier de l'université de Montréal (Hôpital Notre-Dame), Montréal, QC, Canada, 2Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, 3Centre Hospitalier Universitaire de Québec, pavillon CHUL, Sainte-Foy, QC, Canada, 4Rheumatology, Institut de Rhumatologie de Montréal, Montreal, QC, Canada

    Background/Purpose: No long term head-to-head comparative studies of anti-TNF agents in psoriatic arthritis have been published. Controversy exists over the selection of initial biologic therapy…
  • Abstract Number: 2388 • 2013 ACR/ARHP Annual Meeting

    Predictive Factors Of Relapse Or Persistent Stable Remission For Rheumatoid Arthritis (RA) Patients In Remission in a TNF Blocker-Spacing Strategy Trial (STRASS Trial)

    Thao Pham1, Jacques Morel2, Toni Alfaiate3, Emmanuelle Dernis4, Philippe Gaudin5, Olivier Brocq6, Elisabeth Solau-Gervais7, Jean-Marie Berthelot8, Jean-Charles Balblanc9, Xavier Mariette10, Florence Tubach11 and Bruno Fautrel12, 1Rheumatology Department, Sainte Marguerite Hospital, Marseille, France, 2Department of Rheumatology, Hôpital Lapeyronie, Montpellier, France, 3Biostatistics, Bichat Hospital, AP-HP, Paris, France, 4Le Mans Hospital, Le Mans, France, 5Rheumatology Department, CHU Hôpital Sud, Grenoble Teaching Hospital, Echirolles, France, 6Hospital of Princesse Grâce de Monaco, Monaco, France, 7Rheumatology, University Hospital of Poitiers, Poitiers, France, 8Rheumatology Unit, Nantes University Hospital, Nantes, France, 9Rheumatology, Centre Hospitalier Général de Belfort, Belfort, France, 10Rheumatology Service, Bicêtre University Hospital, Le Kremlin Bicetre, France, 11INSERM, Universite Paris Diderot, Paris, France, 12Paris 6 – Pierre et Marie Curie University; AP-HP, Rheumatology, Pitié-Salpêtrière Hospital, - GRC-UPMC 08 – EEMOIS, Paris, France

    Background/Purpose: The STRASS trial was a 18-month randomized controlled trial, conducted in established RA patients in DAS28 remission with etanercept (ETA) or adalimumab (ADA), comparing…
  • Abstract Number: 1737 • 2013 ACR/ARHP Annual Meeting

    Association Of HLA-DRB1 Alleles With Clinical Responses To The Anti-Interleukin−17A Monoclonal Antibody Secukinumab In a Cohort Of Patients With Active Rheumatoid Arthritis:  An Exploratory Phase 2 Biomarker Study

    Gerd Burmester1, Patrick Durez2, Galina Shestakova3, Yue Li4, Amanda Wang5, Steve Lewitzky5, Irina Koroleva5, David Lee6 and Wolfgang Hueber7, 1Department of Rheumatology & Clinical Immunology, Charité-Universitätsmedizin Berlin, Free University and Humboldt University of Berlin, Berlin, Germany, 2Université Catholique de Louvain, Brussels, Belgium, 3Kaluga State Pedagogical Tsiolkovsky University, Kaluga, Russia, 4IIS, Novartis Pharma AG, Basel, Switzerland, 5Novartis Pharma AG, Cambridge, MA, 6Novartis Pharma AG, Basel, Switzerland, 7Translational Medicine Autoimmunity, Novartis Pharma AG, Basel, Switzerland

    Background/Purpose: The shared epitope (SE) may play a functional role in RA via Th17/interleukin (IL)-17 polarization (Holoshitz et al. FEBS Lett 2011;585:3619-26). Two phase 2…
  • Abstract Number: 1038 • 2013 ACR/ARHP Annual Meeting

    Impact Of Biological Treatment On Overall Mortality and On Incidence Of Second Cancers In Arthritis Patients – A Follow-Up Study From The Danish Danbio Registry

    Lene Dreyer1, Lene Mellemkjær2, Inger Marie Jensen Hansen3 and Merete Lund Hetland4, 1Internal Medicine - Rheumatology Section, Copenhagen University Hospital at Gentofte, Copenhagen, Denmark, 2Danish Cancer Society Research Center, Copenhagen, Denmark, 3Department of Reumatology, OUH Svendborg Hospital, Svendborg, Denmark, 4Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, The Danish Rheumatologic Database (DANBIO), Glostrup Hospital., Copenhagen, Denmark

    Background/Purpose: It is largely unknown whether it is safe to treat arthritis patients with a previous malignancy with biologics. Only a few studies have address…
  • Abstract Number: 277 • 2013 ACR/ARHP Annual Meeting

    Childhood Arthritis and Rheumatology Research Alliance (CARRA) Standardized Consensus Treatment Plans for New Onset Polyarticular Juvenile Idiopathic Arthritis

    Sarah Ringold1, Pamela F. Weiss2, Robert A. Colbert3, Esi Morgan DeWitt4, Tzielan C. Lee5, Karen Onel6, Sampath Prahalad7, Rayfel Schneider8, Susan Shenoi9, Richard K. Vehe10 and Yukiko Kimura11, 1Pediatrics, Seattle Children's Hospital/Univ of Washington, Seattle, WA, 2Rheumatology, The Children's Hospital of Philadelphia, Philadelphia, PA, 3NIAMS NIH, Bethesda, MD, 4Department of Pediatrics, Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 5Pediatric Rheumatology, Stanford University School of Medicine, Stanford, CA, 6Pediatric Rheumatology, University of Chicago Hospitals, Chicago, IL, 7Pediatrics, Emory Children's Center, Atlanta, GA, 8Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati, OH, Canada, 9Pediatric Rheumatology, Seattle Children's Hospital, University of Washington, Seattle, WA, 10Department of Pediatrics, University of Minnesota, Minneapolis, MN, 11Pediatric Rheumatology, Joseph M Sanzari Children’s Hospital, Hackensack University Medical Center, Hackensack, NJ

    Background/Purpose:   There is no standardized approach to the initial treatment of polyarticular juvenile idiopathic arthritis (pJIA) among North American pediatric rheumatologists. Understanding the comparative…
  • Abstract Number: 2367 • 2013 ACR/ARHP Annual Meeting

    Discontinuation Of Biological Therapy Due To Adverse Drug Reactions In Rheumatoid Arthritis Patients: 12 Years Follow-Up

    Luis Rodriguez-Rodriguez1, Leticia Leon2, Zulema Rosales2, Cristina Lajas2, Lucía Arietti2, Ana B. Rodríguez-Cambrón2, Cristina Martínez-Prada2, Jose María Leal2, Pilar Macarrón2, Gloria Candelas2, Juan A. Jover2 and Lydia Abásolo2, 1Hospital Clínico San Carlos, Department of Rheumatology, Madrid, Spain, 2Rheumatology, Hospital Clínico San Carlos, Madrid, Spain

    Background/Purpose: To describe in a cohort of rheumatoid arthritis (RA) patients followed up to 12 years, in standard clinical practice, the rate of biological agents…
  • Abstract Number: 1555 • 2013 ACR/ARHP Annual Meeting

    Anti-TNF Drug Survival In Psoriatic Arthritis Patients Treated In Ordinary Clinical Practice

    Glenn Haugeberg1, Andreas P. Diamantopoulos1, Agnete Gulati2, Mari Hoff3 and Arthur Kavanaugh4, 1Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, 2Rheumatology, St.Olavs Hospital, Trondheim, Norway, 3Rheumatology, St Olavs Hospital, Trondheim, Norway, 4University of California San Diego, San Diego, CA

    Background/Purpose: The use of TNF-inhibitors in psoriatic arthritis (PsA) has been shown to improve clinical and radiographic outcome in randomized controlled trials (RCT) and shown…
  • Abstract Number: 1051 • 2013 ACR/ARHP Annual Meeting

    Sociodemographic, Health System, and Community Characteristics Associated With Initiation Of Biological Dmards In RA

    Edward H. Yelin1, Chris Tonner2, Seoyoung C. Kim3, Jeffrey N. Katz4, John Z. Ayanian5 and Daniel H. Solomon6, 1Medicine, UC San Francisco, San Francisco, CA, 2Medicine, University of California, San Francisco, San Francisco, CA, 3Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 4Rheumatology and Orthopedics, Brigham and Women's Hospital, Boston, MA, 5Brigham and Women's Hospital, Boston, MA, 6Division of Pharmacoepidemiology, Harvard Medical School, Brigham and Women's Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA

    Background/Purpose: The use of biologic DMARDs for RA has improved outcomes, but it is unknown whether there are disparities in initiation of these agents by…
  • « Previous Page
  • 1
  • …
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology